Drug approvals through the first half of 2026 totaled 261, making it the third-best H1 on record and highlighting acceleration in June. The 64 approvals logged in June marked the highest single month in the first-six-months period, with the month outpacing May’s 43. For biotech pipeline teams, the data points to a regulator-heavy calendar into mid-year, which can affect commercial planning, launch sequencing, and how late-stage studies are positioned against the current approval throughput.